XOMA Co. (NASDAQ:XOMA - Get Free Report) CEO Owen Hughes sold 21,881 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
XOMA Price Performance
Shares of XOMA opened at $29.71 on Thursday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA Co. has a 52-week low of $14.33 and a 52-week high of $33.78. The business has a fifty day moving average of $28.60 and a 200 day moving average of $26.84.
XOMA (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $11.09 million for the quarter, compared to analysts' expectations of $8.37 million. On average, research analysts predict that XOMA Co. will post -0.79 EPS for the current fiscal year.
Wall Street Analyst Weigh In
New post-election stock warning from Wall Street
From Chaikin Analytics | Ad
If you’re holding U.S. stocks, it may be time to brace for impact.
The S&P 500 crossed 6,000 for the first time in history...
Not everything is as rosy as it seems on Wall Street.
Several brokerages recently weighed in on XOMA. StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Wednesday, August 14th. HC Wainwright restated a "buy" rating and set a $117.00 target price on shares of XOMA in a research report on Wednesday, October 23rd.
Read Our Latest Stock Report on XOMA
Institutional Trading of XOMA
Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after buying an additional 795 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in XOMA in the first quarter worth $212,000. Rhumbline Advisers lifted its position in shares of XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of XOMA during the third quarter valued at $516,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Institutional investors own 95.92% of the company's stock.
XOMA Company Profile
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
